Our History
Hangzhou Grand Biopharmaceuticals, a subsidiary of Grand Life Sciences Group, has become the controlling shareholder of Qingdao Yihao through equity transfer and capital increase. The two parties jointly plan the entire probiotics health industry chain and strengthen R&D, production and market collaboration.
It has been approved as Qingdao Lactic Acid Bacteria Industrialization R&D Expert Workstation to build an integrated innovation platform for industry, academia and research.
Animal Bifidobacterium NSY0201 (patent number: 202110622102.7) has been granted a patent to expand the application of probiotics in the field of immune health.
The independently developed Lactobacillus paracasei NSL0201 (patent number: 2021106221370) was approved, promoting the development of functional foods.
It was rated as a "specialized, sophisticated and innovative" enterprise in Qingdao, and its technical strength and industrial contribution were authoritatively recognized by the government.
Shandong Weifang Changle Factory officially started production, realizing large-scale production of core products such as liquid bacterial agents and highly active bacterial powders.
The construction of Shandong Qingdao Pingdu Factory has started, with a planned annual production capacity of 10,000 tons of probiotic raw materials and end products.
Received RMB 40 million of equity investment from Shandong Science and Technology Innovation Momentum Venture Capital Fund to accelerate technology transformation and market expansion.
Qingdao Norson Biotech was incubated and established to focus on the research and development, production and OEM of food-grade probiotics, and to build a professional industrial layout.
Qingdao Yihao Biotechnology Co., Ltd. was registered and established, starting the research and development and industrialization of microbial technology.
Development Context
Deepening of Technology
From the technology accumulation of Yihao Bio to the focus of Norson Bio on the probiotics segment, a complete technology chain of patented strains, large-scale production, and diversified scenario applications has been formed.
Capacity Expansion
Relying on the two major production bases in Qingdao Pingdu and Weifang Changle, a full-chain supply capacity covering raw materials to terminals has been built.
Capital Empowerment
From the investment of the Science and Technology Innovation Fund to the holding of Yuanda Group, capital helps accelerate the industrialization of technology and market expansion.
Strategic Leap
Joining the Yuanda Life Science system, integrating resources to deepen the probiotics health field, and moving towards a national layout.
